302 related articles for article (PubMed ID: 22566373)
1. Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.
Mato AR; Feldman T; Goy A
Oncologist; 2012; 17(5):694-707. PubMed ID: 22566373
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib for the treatment of non-Hodgkin's lymphoma.
Bose P; Batalo MS; Holkova B; Grant S
Expert Opin Pharmacother; 2014 Nov; 15(16):2443-59. PubMed ID: 25263936
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.
O'Connor OA
Curr Treat Options Oncol; 2004 Aug; 5(4):269-81. PubMed ID: 15233904
[TBL] [Abstract][Full Text] [Related]
5. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitors in mantle cell lymphoma.
Holkova B; Grant S
Best Pract Res Clin Haematol; 2012 Jun; 25(2):133-41. PubMed ID: 22687449
[TBL] [Abstract][Full Text] [Related]
8. The ubiquitin proteasome pathway from bench to bedside.
Orlowski RZ
Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
[TBL] [Abstract][Full Text] [Related]
9. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
O'Connor OA
Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.
Paoluzzi L; O'Connor OA
BioDrugs; 2006; 20(1):13-23. PubMed ID: 16573348
[TBL] [Abstract][Full Text] [Related]
11. The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
Orlowski RZ
Oncology (Williston Park); 2011 Nov; 25 Suppl 2(12 0 2):56-64. PubMed ID: 25188482
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
Mendler JH; Kelly J; Voci S; Marquis D; Rich L; Rossi RM; Bernstein SH; Jordan CT; Liesveld J; Fisher RI; Friedberg JW
Ann Oncol; 2008 Oct; 19(10):1759-64. PubMed ID: 18504251
[TBL] [Abstract][Full Text] [Related]
13. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
14. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
15. Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Orlowski RZ; Zeger EL
Expert Opin Investig Drugs; 2006 Feb; 15(2):117-30. PubMed ID: 16433592
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors in the treatment of B-cell malignancies.
Schenkein D
Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
[TBL] [Abstract][Full Text] [Related]
17. Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Mujtaba T; Dou QP
Discov Med; 2011 Dec; 12(67):471-80. PubMed ID: 22204764
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
O'Connor OA; Czuczman MS
Leuk Lymphoma; 2008; 49 Suppl 1():59-66. PubMed ID: 18821434
[TBL] [Abstract][Full Text] [Related]
20. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
